Mindbio Therapeutics, a subsidiary of cannabis and psychedelics holding company Blackhawk Growth Corp. BLRZF, together with research collaborators at the University of Auckland, have received NZ$1.44 million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD).
The state agency grant funding followed the successful completion of a phase 1 clinical trial in 80 healthy participants. The data from this study is currently being assembled and MindBio is set to further announce the new findings.
Currently, the company is exclusively focused in the development of psychedelic microdosing clinical trials with scientific collaborators at the University of Auckland towards the creation of intellectual property and novel treatments for mental health conditions which are suit for commercialization and use in patients in need.
Blackhawk’s CEO Frederick Pels expressed: “We are proud of the work of our scientific collaborators and the substantial support shown is testament to the calibre of scientists leading the project. We are determined to develop game-changing treatments for mental health conditions.”
Photo by Paola Chaaya on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.